| Revised international prognostic scoring system for myelodysplastic syndromes PL Greenberg, H Tuechler, J Schanz, G Sanz, G Garcia-Manero, F Solé, ... Blood 120 (12), 2454-2465, 2012 | 1778 | 2012 |
| Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. L Malcovati, U Germing, A Kuendgen, MG Della Porta, C Pascutto, ... Journal of clinical oncology 25 (23), 3503-3510, 2007 | 1076 | 2007 |
| Clinical and biological implications of driver mutations in myelodysplastic syndromes E Papaemmanuil, M Gerstung, L Malcovati, S Tauro, G Gundem, ... Blood, The Journal of the American Society of Hematology 122 (22), 3616-3627, 2013 | 1056 | 2013 |
| Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts E Papaemmanuil, M Cazzola, J Boultwood, L Malcovati, P Vyas, D Bowen, ... New England Journal of Medicine 365 (15), 1384-1395, 2011 | 945 | 2011 |
| Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making L Malcovati, MGD Porta, C Pascutto, R Invernizzi, M Boni, E Travaglino, ... Journal of Clinical Oncology 23 (30), 7594-7603, 2005 | 932 | 2005 |
| Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet L Malcovati, E Hellström-Lindberg, D Bowen, L Adès, J Cermak, ... Blood 122 (17), 2943-2964, 2013 | 485 | 2013 |
| CD34+ and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure M Valgimigli, GM Rigolin, A Fucili, MD Porta, O Soukhomovskaia, ... Circulation 110 (10), 1209-1212, 2004 | 455 | 2004 |
| Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms L Malcovati, E Papaemmanuil, DT Bowen, J Boultwood, MG Della Porta, ... Blood, The Journal of the American Society of Hematology 118 (24), 6239-6246, 2011 | 383 | 2011 |
| Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome M Jadersten, L Malcovati, I Dybedal, M Giovanni Della Porta, R Invernizzi, ... Journal of Clinical Oncology 26 (21), 3607-3613, 2008 | 304 | 2008 |
| Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative … F Passamonti, E Rumi, D Pietra, MGD Porta, E Boveri, C Pascutto, ... Blood 107 (9), 3676-3682, 2006 | 291 | 2006 |
| Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective study J Porter, R Galanello, G Saglio, EJ Neufeld, E Vichinsky, MD Cappellini, ... European journal of haematology 80 (2), 168-176, 2008 | 290 | 2008 |
| Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile M Valgimigli, GM Rigolin, C Cittanti, P Malagutti, S Curello, G Percoco, ... European heart journal 26 (18), 1838-1845, 2005 | 287 | 2005 |
| The genetic basis of myelodysplasia and its clinical relevance M Cazzola, MG Della Porta, L Malcovati Blood, The Journal of the American Society of Hematology 122 (25), 4021-4034, 2013 | 279 | 2013 |
| Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia J Boultwood, J Perry, A Pellagatti, M Fernandez-Mercado, ... Leukemia 24 (5), 1062-1065, 2010 | 259 | 2010 |
| Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) L Malcovati, MG Della Porta, C Strupp, I Ambaglio, A Kuendgen, ... Haematologica 96 (10), 1433-1440, 2011 | 235 | 2011 |
| Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes MG Della Porta, L Malcovati, E Boveri, E Travaglino, D Pietra, C Pascutto, ... Journal of clinical oncology 27 (5), 754-762, 2009 | 233 | 2009 |
| Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes AA Van De Loosdrecht, C Alhan, MC Béné, MG Della Porta, AM Dräger, ... haematologica 94 (8), 1124-1134, 2009 | 230 | 2009 |
| SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts L Malcovati, M Karimi, E Papaemmanuil, I Ambaglio, M Jädersten, ... Blood, The Journal of the American Society of Hematology 126 (2), 233-241, 2015 | 228 | 2015 |
| Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome MG Della Porta, L Malcovati, C Strupp, I Ambaglio, A Kuendgen, ... haematologica 96 (3), 441-449, 2011 | 221 | 2011 |
| WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) EP Alessandrino, MG Della Porta, A Bacigalupo, MT Van Lint, M Falda, ... Blood, The Journal of the American Society of Hematology 112 (3), 895-902, 2008 | 213 | 2008 |
